Company

Clinuvel Pharmaceuticals Limited

Headquarters: Melbourne, VIC, Australia

CEO: Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA

ASX: CUV -1.17%

Market Cap

A$851.7 Million

AUD as of July 1, 2024

US$567.2 Million

Market Cap History

Clinuvel Pharmaceuticals Limited market capitalization over time

Evolution of Clinuvel Pharmaceuticals Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Clinuvel Pharmaceuticals Limited

Detailed Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRà‰NUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Clinuvel Pharmaceuticals Limited has the following listings and related stock indices.


Stock: ASX: CUV wb_incandescent

Stock: FSX: UR9 wb_incandescent

Stock: Munich: UR9 wb_incandescent

Details

Headquarters:

535 Bourke Street

Level 11

Melbourne, VIC 3000

Australia

Phone: 61 3 9660 4900

Fax: 61 3 9660 4909